Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06082037

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Oral Belumosudil in Adults With Chronic Lung Allograft Dysfunction After Bilateral Lung Transplant, Followed by Open-label Extensions

Led by Sanofi · Updated on 2026-06-02

180

Participants Needed

80

Research Sites

87 weeks

Total Duration

On this page

Sponsors

S

Sanofi

Lead Sponsor

M

Meiji Seika Pharma Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and safety of belumosudil compared with placebo in adults with chronic lung allograft dysfunction (CLAD) who are at least one year after a bilateral lung transplant. This phase 3, double-blind, randomized, placebo-controlled study includes participants of both genders aged 18 years and older who continue to have worsening CLAD despite azithromycin therapy. The study is conducted across multiple countries and centers to gather comprehensive data on treatment outcomes. Participants will be randomly assigned to receive either 200 mg of belumosudil orally once daily or a placebo, both alongside azithromycin and the standard immunosuppression regimen. The treatment period lasts up to 26 weeks for those not entering the open-label extension (OLE) and up to 52 weeks for those who do. Participants entering the long-term OLE will continue treatment and study visits every 12 weeks according to protocol. Participants will attend up to 10 visits during the initial phase or up to 16 visits if they enter the OLE. Assessments include lung function tests such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), 6-minute walk distance, and quality of life questionnaires like the Saint George Respiratory Questionnaire (SGRQ). Researchers will monitor changes in these measures, track adverse events, and evaluate the time to CLAD progression, re-transplantation, or death. Study participation may continue for several months with ongoing safety monitoring.

CONDITIONS

Brief Title

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is at least 1 year post bilateral lung transplant at screening
  • Participants have CLAD Stage 1 or 2 with FEV1 from greater than 50% to 80% of post-transplant baseline at screening and randomization
  • Participants have received at least 8 weeks of azithromycin (250 mg/day or more, at least 3 times a week) before randomization
  • Adults aged 18 years or older
Not Eligible

You will not qualify if you...

  • FEV1 is 50% or less of post-transplant baseline value (CLAD Stage 3 or 4)
  • Lung function decline caused by non-CLAD reasons such as acute lung rejection (greater than A1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 26 weeks

Participants receive oral tablets of belumosudil or placebo daily along with azithromycin to treat chronic lung allograft dysfunction.

Regular visits during the 26-week treatment period

Follow-up

Duration - Up to 7 days after treatment ends

Participants are monitored for safety and outcomes up to 7 days after the last dose of study drug.

1 follow-up visit

Trial Site Locations

Total: 80 locations

1

University of Alabama at Birmingham- Site Number : 8400026

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

St. Joseph's Hospital and Medical Center- Site Number : 8400019

Phoenix, Arizona, United States, 85013

Actively Recruiting

3

University of California Los Angeles Medical Center- Site Number : 8400020

Los Angeles, California, United States, 90095

Actively Recruiting

4

Stanford University Medical Center- Site Number : 8400008

Stanford, California, United States, 94305

Actively Recruiting

5

Mayo Clinic in Florida- Site Number : 8400031

Jacksonville, Florida, United States, 32224

Actively Recruiting

6

Jackson Memorial Hospital- Site Number : 8400030

Miami, Florida, United States, 33136

Actively Recruiting

7

AdventHealth Orlando- Site Number : 8400023

Orlando, Florida, United States, 32803

Actively Recruiting

8

Tampa General Hospital - Tampa - General Circle- Site Number : 8400015

Tampa, Florida, United States, 33606

Actively Recruiting

9

Emory University Hospital- Site Number : 8400027

Atlanta, Georgia, United States, 30324

Actively Recruiting

10

Northwestern University- Site Number : 8400003

Chicago, Illinois, United States, 60611

Actively Recruiting

11

Loyola University Medical Center- Site Number : 8400025

Maywood, Illinois, United States, 60153

Actively Recruiting

12

University of Iowa- Site Number : 8400032

Iowa City, Iowa, United States, 52242

Actively Recruiting

13

University of Maryland School of Medicine - Baltimore- Site Number : 8400009

Baltimore, Maryland, United States, 21201

Actively Recruiting

14

Johns Hopkins Hospital- Site Number : 8400034

Baltimore, Maryland, United States, 21287

Actively Recruiting

15

Brigham & Women's Hospital- Site Number : 8400016

Boston, Massachusetts, United States, 02115

Actively Recruiting

16

University of Michigan Health System - Ann Arbor- Site Number : 8400014

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

17

Corewell Health - Grand Rapids - Michigan Street Northeast- Site Number : 8400010

Grand Rapids, Michigan, United States, 49503

Actively Recruiting

18

NYU Perlmutter Cancer Center - Energy Building- Site Number : 8400001

New York, New York, United States, 10016

Actively Recruiting

19

Icahn School of Medicine at Mount Sinai- Site Number : 8400037

New York, New York, United States, 10029

Actively Recruiting

20

Columbia University Irving Medical Center- Site Number : 8400002

New York, New York, United States, 10032

Actively Recruiting

21

Montefiore Medical Center - Moses Campus- Site Number : 8400036

The Bronx, New York, United States, 10467

Actively Recruiting

22

Duke University Medical Center- Site Number : 8400017

Durham, North Carolina, United States, 27710

Actively Recruiting

23

Cleveland Clinic - Cleveland- Site Number : 8400005

Cleveland, Ohio, United States, 44195

Actively Recruiting

24

The Ohio State University- Site Number : 8400028

Columbus, Ohio, United States, 43210

Actively Recruiting

25

Penn Medicine: University of Pennsylvania Health System- Site Number : 8400006

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

26

Temple University Hospital- Site Number : 8400007

Philadelphia, Pennsylvania, United States, 19140

Actively Recruiting

27

Vanderbilt University Medical Center- Site Number : 8400018

Nashville, Tennessee, United States, 37232

Actively Recruiting

28

University of Texas - Southwestern Medical Center- Site Number : 8400013

Dallas, Texas, United States, 75390

Actively Recruiting

29

Baylor College of Medicine- Site Number : 8400024

Houston, Texas, United States, 77030

Actively Recruiting

30

Houston Methodist Hospital- Site Number : 8400021

Houston, Texas, United States, 77030

Actively Recruiting

31

University Health System - San Antonio- Site Number : 8400035

San Antonio, Texas, United States, 78229

Actively Recruiting

32

Inova Fairfax Hospital- Site Number : 8400004

Falls Church, Virginia, United States, 22042

Actively Recruiting

33

Investigational Site Number : 0360003

Darlinghurst, New South Wales, Australia, 2010

Actively Recruiting

34

Investigational Site Number : 0360001

Brisbane, Queensland, Australia, 4032

Actively Recruiting

35

Investigational Site Number : 0360002

Murdoch, Western Australia, Australia, 6150

Actively Recruiting

36

Investigational Site Number : 0400001

Vienna, Austria, 1090

Actively Recruiting

37

Investigational Site Number : 0560001

Leuven, Belgium, 3000

Actively Recruiting

38

Investigational Site Number : 0560002

Yvoir, Belgium, 5530

Actively Recruiting

39

Investigational Site Number : 1240002

Edmonton, Alberta, Canada, T6G 2B7

Actively Recruiting

40

Investigational Site Number : 1240001

Vancouver, British Columbia, Canada, V5Z 1M9

Actively Recruiting

41

Investigational Site Number : 1240004

Toronto, Ontario, Canada, M5G 2C4

Actively Recruiting

42

Investigational Site Number : 1560004

Beijing, China, 100029

Actively Recruiting

43

Investigational Site Number : 1560002

Chengdu, China, 610072

Actively Recruiting

44

Investigational Site Number : 1560008

Fuzhou, China, 350001

Actively Recruiting

45

Investigational Site Number : 1560007

Guangzhou, China, 510163

Actively Recruiting

46

Investigational Site Number : 1560001

Hangzhou, China, 310009

Actively Recruiting

47

Investigational Site Number : 1560005

Hefei, China, 230001

Actively Recruiting

48

Investigational Site Number : 1560009

Shanghai, China, 200433

Actively Recruiting

49

Investigational Site Number : 1560003

Wuxi, China, 214023

Actively Recruiting

50

Investigational Site Number : 1560006

Zhengzhou, China, 450052

Actively Recruiting

51

Investigational Site Number : 2030002

Olomouc, Czechia, 779 00

Actively Recruiting

52

Investigational Site Number : 2030001

Prague, Czechia, 150 06

Actively Recruiting

53

Investigational Site Number : 2080001

Copenhagen, Denmark, 2100

Actively Recruiting

54

Investigational Site Number : 2460001

Helsinki, Finland, 00029

Actively Recruiting

55

Investigational Site Number : 2500005

Le Plessis-Robinson, France, 92350

Actively Recruiting

56

Investigational Site Number : 2500006

Marseille, France, 13915

Actively Recruiting

57

Investigational Site Number : 2500004

Paris, France, 75018

Actively Recruiting

58

Investigational Site Number : 2500002

Pessac, France, 33604

Actively Recruiting

59

Investigational Site Number : 2500003

Saint-Herblain, France, 44800

Actively Recruiting

60

Investigational Site Number : 2500001

Suresnes, France, 92151

Actively Recruiting

61

Investigational Site Number : 2760003

Munich, Germany, 81337

Actively Recruiting

62

Investigational Site Number : 3480001

Budapest, Hungary, 1085

Actively Recruiting

63

Investigational Site Number : 3760001

Petah Tikva, Israel, 4941492

Actively Recruiting

64

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano-Site Number : 3800001

Milan, Milano, Italy, 20122

Actively Recruiting

65

Investigational Site Number : 3800005

Padua, Padova, Italy, 35128

Actively Recruiting

66

IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione)-Site Number : 3800004

Palermo, Italy, 90133

Actively Recruiting

67

Fondazione IRCCS Policlinico San Matteo-Site Number : 3800003

Pavia, Italy, 27100

Actively Recruiting

68

Azienda Ospedaliera Universitaria Senese UOC Malattie Respiratorie e Trapianto Polmonare-Site Number : 3800002

Siena, Italy, 53100

Actively Recruiting

69

Investigational Site Number : 3920001

Tokyo, Japan, 113-8654

Actively Recruiting

70

Investigational Site Number : 5280001

Groningen, Netherlands, 9713 GR

Actively Recruiting

71

Investigational Site Number : 5780001

Oslo, Norway, 0372

Actively Recruiting

72

Investigational Site Number : 4100004

Yangsan, Gyeongsangnam-do, South Korea, 50612

Actively Recruiting

73

Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, South Korea, 03080

Actively Recruiting

74

Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, South Korea, 03722

Actively Recruiting

75

Investigational Site Number : 4100003

Seoul, Seoul-teukbyeolsi, South Korea, 06351

Actively Recruiting

76

Investigational Site Number : 7240002

A Coruña, A Coruña [La Coruña], Spain, 15006

Actively Recruiting

77

Investigational Site Number : 7240003

Barcelona, Barcelona [Barcelona], Spain, 08035

Actively Recruiting

78

Investigational Site Number : 7240001

Santander, Cantabria, Spain, 39008

Actively Recruiting

79

Investigational Site Number : 7240004

Valencia, Spain, 46026

Actively Recruiting

80

Investigational Site Number : 7520001

Gothenburg, Sweden, 413 45

Actively Recruiting

Loading map...

Research Team

T

Trial Transparency email recommended (Toll free number for US & Canada)

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

The Use of Extracorporeal Photopheresis as Immunomodulatory ...

Antibody-mediated Rejection

Actively Recruiting

7 locations

A Prospective, Randomized Clinical Trial to Evaluate the Fea...

Lung Transplant Rejection

Actively Recruiting

1 location

Advanced Immunoclinical Phenotyping of Rejection in Lung Tra...

Lung Transplant Rejection

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here